Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study

Background - EORTC (European Organisation of Research and Treatment of Cancer) 62024 is a phase III randomised trial evaluating adjuvant imatinib in patients with gastrointestinal stromal tumours (GISTs) and no evidence of residual disease after surgery in 908 patients from 11 countries participated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hohenberger, Peter (VerfasserIn) , Bonvalot, Sylvie (VerfasserIn) , van Coevorden, Frits (VerfasserIn) , Rutkowski, Pjotr (VerfasserIn) , Stoeckle, Eberhard (VerfasserIn) , Olungu, Christine (VerfasserIn) , Litiere, Saskia (VerfasserIn) , Wardelmann, Eva (VerfasserIn) , Gronchi, Alessandro (VerfasserIn) , Casali, Paolo G. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 31 August 2019
In: European journal of cancer
Year: 2019, Jahrgang: 120, Pages: 47-53
ISSN:1879-0852
DOI:10.1016/j.ejca.2019.07.028
Online-Zugang:Verlag, Volltext: https://doi.org/10.1016/j.ejca.2019.07.028
Verlag: http://www.sciencedirect.com/science/article/pii/S0959804919304472
Volltext
Verfasserangaben:Peter Hohenberger, Sylvie Bonvalot, Frits van Coevorden, Pjotr Rutkowski, Eberhard Stoeckle, Christine Olungu, Saskia Litiere, Eva Wardelmann, Alessandro Gronchi, Paolo Casali

MARC

LEADER 00000caa a2200000 c 4500
001 1689519002
003 DE-627
005 20251220132533.0
007 cr uuu---uuuuu
008 200206s2019 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.ejca.2019.07.028  |2 doi 
035 |a (DE-627)1689519002 
035 |a (DE-599)KXP1689519002 
035 |a (OCoLC)1341303833 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hohenberger, Peter  |d 1953-  |e VerfasserIn  |0 (DE-588)1025311469  |0 (DE-627)72202875X  |0 (DE-576)370195574  |4 aut 
245 1 0 |a Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study  |c Peter Hohenberger, Sylvie Bonvalot, Frits van Coevorden, Pjotr Rutkowski, Eberhard Stoeckle, Christine Olungu, Saskia Litiere, Eva Wardelmann, Alessandro Gronchi, Paolo Casali 
264 1 |c 31 August 2019 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 06.02.2020 
520 |a Background - EORTC (European Organisation of Research and Treatment of Cancer) 62024 is a phase III randomised trial evaluating adjuvant imatinib in patients with gastrointestinal stromal tumours (GISTs) and no evidence of residual disease after surgery in 908 patients from 11 countries participated. As surgical treatment aspects (tumour rupture and incomplete resection) contribute to the risk of recurrence, the data of primary surgery were reviewed. - Methods - The surgical record, local pathology report and a surgical questionnaire on details of the operation had to be completed when patients entered the study. Surgeons from 5 countries, covering 8 languages, reviewed the full set of data being available from 793 patients (87.3%). - Results - A known GIST was the reason for surgery in only 58% of the cases, and 12% of the patients were treated as an emergency. The R0-resection rate was 87%. The extent of resection was local excision in 17%, segmental resection in 59%, full-organ resection in 11% and multivisceral resection in 11%, with lymphadenectomy performed in 24% of the patients. Shelling out of the tumour was performed in 9.7%, and the proportion of tumours removed in parts was higher in the endoscopy/laparoscopy group. The incidence of tumour rupture (representing M1) was 9%. The consistency between preoperative and intraoperative findings was 82%. The postoperative complication rate was 7.3%. - Conclusion - The standardisation of surgery in this study was inferior. Given the review data, 18% of the patients should not have participated in the trial. Quality of surgery and improperly reported intraoperative details might influence the trial results. A detailed surgical questionnaire filled out by the surgeon is mandatory before entering the patient in an adjuvant trial in GIST. 
650 4 |a Adjuvant treatment 
650 4 |a Gastro-intestinal stromal tumor 
650 4 |a Imatinib 
650 4 |a Quality assessment 
650 4 |a Surgical oncology trials 
650 4 |a Surgical reporting 
650 4 |a Surgical treatment 
700 1 |a Bonvalot, Sylvie  |e VerfasserIn  |0 (DE-588)1136049533  |0 (DE-627)891103368  |0 (DE-576)49028552X  |4 aut 
700 1 |a van Coevorden, Frits  |e VerfasserIn  |4 aut 
700 1 |a Rutkowski, Pjotr  |e VerfasserIn  |4 aut 
700 1 |a Stoeckle, Eberhard  |e VerfasserIn  |4 aut 
700 1 |a Olungu, Christine  |e VerfasserIn  |4 aut 
700 1 |a Litiere, Saskia  |e VerfasserIn  |4 aut 
700 1 |a Wardelmann, Eva  |d 1964-  |e VerfasserIn  |0 (DE-588)121391175  |0 (DE-627)081277458  |0 (DE-576)292686145  |4 aut 
700 1 |a Gronchi, Alessandro  |e VerfasserIn  |0 (DE-588)1160261903  |0 (DE-627)1023412829  |0 (DE-576)505812061  |4 aut 
700 1 |a Casali, Paolo G.  |e VerfasserIn  |0 (DE-588)1126666475  |0 (DE-627)88126086X  |0 (DE-576)484652117  |4 aut 
773 0 8 |i Enthalten in  |t European journal of cancer  |d Amsterdam [u.a.] : Elsevier, 1992  |g 120(2019), Seite 47-53  |w (DE-627)266883400  |w (DE-600)1468190-0  |w (DE-576)090954173  |x 1879-0852  |7 nnas  |a Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study 
773 1 8 |g volume:120  |g year:2019  |g pages:47-53  |g extent:7  |a Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study 
856 4 0 |u https://doi.org/10.1016/j.ejca.2019.07.028  |x Verlag  |x Resolving-System  |3 Volltext  |7 1 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0959804919304472  |x Verlag  |7 1 
951 |a AR 
992 |a 20200206 
993 |a Article 
994 |a 2019 
998 |g 1025311469  |a Hohenberger, Peter  |m 1025311469:Hohenberger, Peter  |d 60000  |e 60000PH1025311469  |k 0/60000/  |p 1  |x j 
999 |a KXP-PPN1689519002  |e 3588518371 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"display":"Hohenberger, Peter","family":"Hohenberger","roleDisplay":"VerfasserIn","given":"Peter","role":"aut"},{"given":"Sylvie","role":"aut","roleDisplay":"VerfasserIn","display":"Bonvalot, Sylvie","family":"Bonvalot"},{"roleDisplay":"VerfasserIn","family":"van Coevorden","display":"van Coevorden, Frits","role":"aut","given":"Frits"},{"role":"aut","given":"Pjotr","roleDisplay":"VerfasserIn","family":"Rutkowski","display":"Rutkowski, Pjotr"},{"roleDisplay":"VerfasserIn","family":"Stoeckle","display":"Stoeckle, Eberhard","role":"aut","given":"Eberhard"},{"family":"Olungu","display":"Olungu, Christine","roleDisplay":"VerfasserIn","given":"Christine","role":"aut"},{"role":"aut","given":"Saskia","roleDisplay":"VerfasserIn","family":"Litiere","display":"Litiere, Saskia"},{"roleDisplay":"VerfasserIn","family":"Wardelmann","display":"Wardelmann, Eva","role":"aut","given":"Eva"},{"given":"Alessandro","role":"aut","roleDisplay":"VerfasserIn","family":"Gronchi","display":"Gronchi, Alessandro"},{"role":"aut","given":"Paolo G.","family":"Casali","display":"Casali, Paolo G.","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study","title":"Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study"}],"note":["Gesehen am 06.02.2020"],"recId":"1689519002","physDesc":[{"extent":"7 S."}],"id":{"doi":["10.1016/j.ejca.2019.07.028"],"eki":["1689519002"]},"language":["eng"],"relHost":[{"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research","roleDisplay":"Herausgebendes Organ"},{"roleDisplay":"Herausgebendes Organ","display":"European School of Oncology","role":"isb"}],"part":{"extent":"7","pages":"47-53","text":"120(2019), Seite 47-53","year":"2019","volume":"120"},"disp":"Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib studyEuropean journal of cancer","pubHistory":["28.1992 -"],"origin":[{"publisher":"Elsevier ; Pergamon Press","dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"titleAlt":[{"title":"EJC online"}],"recId":"266883400","language":["eng"],"id":{"zdb":["1468190-0"],"issn":["1879-0852"],"eki":["266883400"]}}],"name":{"displayForm":["Peter Hohenberger, Sylvie Bonvalot, Frits van Coevorden, Pjotr Rutkowski, Eberhard Stoeckle, Christine Olungu, Saskia Litiere, Eva Wardelmann, Alessandro Gronchi, Paolo Casali"]},"origin":[{"dateIssuedDisp":"31 August 2019","dateIssuedKey":"2019"}]} 
SRT |a HOHENBERGEQUALITYOFS3120